Newsroom

In Bret Stetka's latest piece for the Scientific American, Dr. Nader Sanai weighs in on the challenges of treating glioblastoma and how our accelerated Phase 0/2 clinical trials are delivering new therapeutic options for patients facing the fight of their lives.

The Ivy Brain Tumor Center at Barrow Neurological Institute is taking a bold approach by using Phase 0 testing in patient clinical trials.

There's a glimmer of hope in treating the deadliest form of brain cancer, thanks to a drug trial happening right here in the Valley.

Senator John McCain recently died after fighting glioblastoma, the most aggressive and deadliest kind of brain tumor. Now, other patients whose brain tumors come back have a revolutionary new option for treatment.

A new Ivy Brain Tumor Center study finds that recently-approved drug ribociclib may be an important part of treatment for glioblastoma, one of the deadliest cancers in the world.

The Ben and Catherine Ivy Foundation, in partnership with the Barrow Neurological Institute in Phoenix, has awarded a $50 million grant to establish a new translational science program focusing on early-phase, pharmacodynamic- and pharmacokinetic-driven clinical trials for aggressive brain tumors.

In the last 30 years, a brain tumor expert says median survival has only increased by a few months. Now, a new brain tumor center program is fast-tracking patients into new therapies.

Thanks to a $50 million grant, Barrow Neurological Institute will create a new center to focus on finding a cure and improving outcomes for the deadliest form of brain cancer.

With $50 million from a private foundation, Phoenix-based Barrow Neurological Institute announced Monday that it is opening a center to focus on improving brain-cancer outcomes through experimental clinical trials.

Barrow Neurological Institute, has launched a “phase zero” study that aims to rapidly test drugs on patients whose brain cancer tumors have returned after standard treatment.